Deciphera banks a $52M C round for cancer R&D; Ionis adds $50M milestone from Biogen
→ Waltham, MA-based Deciphera Therapeutics announced that it has banked a $52 million C round to keep fueling its growing pipeline efforts, including its lead drug, still in the early stages of development, a pan-KIT and PDGFR inhibitor dubbed DCC-2618. Viking Global Investors, Redmile Group and Sphera Global Healthcare Fund led the round, joined by Deciphera’s existing investors including New Leaf Venture Partners. Said Deciphera CEO Michael Taylor: “The proceeds of this financing will be used to advance development of DCC-2618 and DCC-3014 into later-stage clinical trials with the goal of delivering new therapies that address key resistance mechanisms to improve cancer treatment outcomes.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.